Allist(SH:688578) Xin Lang Cai Jing·2025-10-09 02:33Group 1 - The core point of the news is that Elysium Pharmaceuticals experienced a decline in stock price, dropping by 5.05% to 104.67 CNY per share, with a trading volume of 284 million CNY and a turnover rate of 0.59%, resulting in a total market capitalization of 47.101 billion CNY [1] - Elysium Pharmaceuticals, established on March 22, 2004, and listed on December 2, 2020, focuses on the research, production, and sales of innovative drugs, with 99.93% of its revenue coming from drug sales [1] Group 2 - From the perspective of major fund holdings, Elysium is heavily weighted in the Huatai-PineBridge fund, which reduced its holdings by 135,900 shares in the second quarter, now holding 587,300 shares, accounting for 4.73% of the fund's net value, making it the fifth-largest holding [2] - The Huatai-PineBridge fund, established on January 21, 2016, has a current scale of 778 million CNY, with a year-to-date return of 47.65% and a one-year return of 34.99% [2]